Journal Article

Current Challenges in the Treatment of Community-Acquired Pneumonia

Thomas M. File

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 38, issue Supplement_1, pages S1-S4
Published in print January 2004 | ISSN: 1058-4838
Published online January 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/378404
Current Challenges in the Treatment of Community-Acquired Pneumonia

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The respiratory fluoroquinolones are considered to be an effective treatment option for community-acquired pneumonia (CAP), and they are the recommended first-line treatment for certain patients. However, the development of resistance associated with the widespread use of these agents has raised concern about the future clinical value of this class of antibiotics. The 4 articles in this supplement issue of Clinical Infectious Diseases reveal clinical data on the safety and efficacy of a fluoroquinolone, levofloxacin, used for the treatment of CAP and CAP-associated infections, including those caused by penicillin- and macrolide-resistant Streptococcus pneumoniae. Future strategies of fluoroquinolone use may improve clinical efficacy and reduce the risk of the emergence of resistance. However, judicious use of antibiotics should always be a high priority when considering treatment of respiratory tract infections.

Journal Article.  2364 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.